ARTICLE | Company News
Dynavax deal
April 24, 2006 7:00 AM UTC
DVAX out-licensed its immunostimulatory sequence (ISS)-based cancer, HBV and HCV therapeutics to Symphony Dynamo. The cancer product is in an ongoing Phase II trial for non-Hodgkin's lymphoma (NHL), w...